| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14740338.2015.1011620 |
| P698 | PubMed publication ID | 25648243 |
| P50 | author | Chris Karampahtsis | Q95981308 |
| P2093 | author name string | Mark E Alexander | |
| Ronke Babalola | |||
| Paul G Hammerness | |||
| P2860 | cites work | Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: a systematic review and meta-analysis of epidemiological studies | Q21260319 |
| Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder | Q22242745 | ||
| ADHD drugs and serious cardiovascular events in children and young adults | Q22250876 | ||
| Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function | Q22252308 | ||
| ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. | Q22253017 | ||
| ADHD and smoking: from genes to brain to behavior | Q28300210 | ||
| Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials | Q33157901 | ||
| Understanding the Effect Size of Lisdexamfetamine Dimesylate for Treating ADHD in Children and Adults | Q47414856 | ||
| Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. | Q48325155 | ||
| Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study | Q49152940 | ||
| Differences across counties in the registered prevalence of autism, ADHD, epilepsy and cerebral palsy in Norway | Q50310194 | ||
| Prevalence of ADHD in a sample of Italian students: A population-based study | Q50705808 | ||
| The prevalence of ADHD: its diagnosis and treatment in four school districts across two states | Q50744163 | ||
| Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder | Q51142196 | ||
| Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder | Q51935749 | ||
| Cardiovascular Health in Childhood: A Statement for Health Professionals From the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association | Q56659248 | ||
| Stimulant Medications and Attention Deficit–Hyperactivity Disorder | Q57302769 | ||
| Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder | Q33819957 | ||
| Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. | Q34045097 | ||
| Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. | Q34063584 | ||
| Methylphenidate and risk of serious cardiovascular events in adults. | Q34154211 | ||
| Amphetamines, atomoxetine and the risk of serious cardiovascular events in adults | Q34575150 | ||
| Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine | Q34647770 | ||
| High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. | Q34685572 | ||
| Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder | Q34733657 | ||
| Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects | Q35000368 | ||
| Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder | Q35954857 | ||
| Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents | Q36002613 | ||
| Stimulants and sudden death: what is a physician to do? | Q36584865 | ||
| Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology | Q36648476 | ||
| Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. | Q37376330 | ||
| Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis | Q37404401 | ||
| Atomoxetine and cerebrovascular outcomes in adults | Q37595282 | ||
| Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children? | Q37756113 | ||
| Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder | Q37784796 | ||
| Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations | Q37941074 | ||
| Attention-Deficit/Hyperactivity Disorder, Stimulant Therapy, and the Patient with Congenital Heart Disease: Evidence and Reason | Q37980690 | ||
| Do stimulants improve functioning in adults with ADHD? A review of the literature | Q38079886 | ||
| Cardiovascular Safety of Stimulants in Children: Findings from Recent Population-Based Cohort Studies | Q38126419 | ||
| Early repair of congenital heart disease associated with increased rate of attention deficit hyperactivity disorder symptoms | Q38152519 | ||
| Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany | Q38431119 | ||
| A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder. | Q39621300 | ||
| Sudden death from cardiac causes in children and young adults | Q40968766 | ||
| Ambulatory Blood Pressure Monitoring in a Cohort of Children Referred with Suspected Hypertension: Characteristics of Children with and without Attention Deficit Hyperactivity Disorder | Q41900772 | ||
| Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. | Q42644322 | ||
| Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. | Q42653907 | ||
| Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database | Q43265649 | ||
| Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis | Q43274881 | ||
| Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder | Q43456283 | ||
| ADHD medication use, adherence, persistence and cost among Texas Medicaid children | Q43971593 | ||
| 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy | Q44042907 | ||
| Attention deficit hyperactivity disorder screening electrocardiograms: a community-based perspective | Q45778429 | ||
| Sudden death and use of stimulant medications in youths. | Q45968311 | ||
| Ventricular arrhythmias in children with attention deficit disorder – a symptom of autonomic imbalance? | Q46055915 | ||
| Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. | Q46503056 | ||
| ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study | Q46713659 | ||
| Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. | Q46778584 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | attention deficit hyperactivity disorder | Q181923 |
| attention | Q6501338 | ||
| P304 | page(s) | 543-551 | |
| P577 | publication date | 2015-02-03 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
| P1476 | title | Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks? | |
| P478 | volume | 14 |
| Q34541036 | Adult ADHD and Comorbid Somatic Disease: A Systematic Literature Review |
| Q39170905 | An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder |
| Q87924411 | Attention-Deficit/Hyperactivity Disorder |
| Q112685281 | Clinical Efficacy Evaluation of Psychological Nursing Intervention Combined with Drugs Treatment of Children with ADHD under Artificial Intelligence |
| Q47677209 | Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD. |
| Q38834913 | Stimulants for impulsive violence in schizophrenia spectrum disordered women: a case series and brief review |
| Q38862420 | The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research |
| Q37416392 | Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries |
Search more.